Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Collagen alpha-2(IV) chain is one of six genetically distinct alpha chains that make up type IV collagen, which forms the major structural meshwork of basement membranes throughout the body[1][4][7]. Encoded by the COL4A2 gene, it pairs in a 2:1 ratio with the alpha-1(IV) chain (COL4A1) to form the predominant type IV collagen network. Beyond its architectural function, a C-terminal cleavage product known as canstatin possesses potent anti-angiogenic and anti-tumor properties by inhibiting endothelial cell proliferation, migration, and survival through integrin antagonism and induction of apoptotic pathways[3][4]. COL4A2 and the major type IV collagen network are critical to tissue integrity, filtration (notably in kidney glomeruli), cell signaling, and repair. Mutations in COL4A2 are associated with multiple diseases, including hereditary vascular syndromes, intracerebral hemorrhage, and other basement membrane pathologies[4][7].
Inhibition of angiogenesis and tumor growth via canstatin fragment, which antagonizes integrins and induces apoptosis in endothelial cells[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Collagen alpha-2(IV) chain (COL4A2).